US$ 25.97
fda import alert 66-80 glp-1 api green list Targets Bulk Substances: What It Means for Compounding and the Peptide Supply Chain FDA Creates Green List of
Description
Results At week 4 after discontinuation, compared with the control group, AOM treatment still had weight loss effect (WMD=0.32 kg, 95% CI3.602.97, P=0.85, I2=83%)
This Homemade Electrolyte Drink recipe is my favourite way to stay hydrated in the summer
Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p=0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p=0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p=0.0315)

Many therapy areas had high growth in days of therapy in 2023 led by GLP-1 agonists driving obesity and diabetes. As the bar chart clearly tells us from the 3rd line on the bottom of the graph, obesity leads the top 30 therapy areas by growth from 2022

Very few include older adults at high risk

Good news for McKesson ($MCK)
